Management of Cardiogenic Shock

Initial Assessment and Diagnosis

The presence of hypotension, tachycardia, sweating, somnolence, and jugular venous distension suggests cardiogenic shock, corresponding to Killip class 4, characterized by severe tissue hypoperfusion, hypotension, low-amplitude pulse, and tachycardia, as recommended by the European Society of Cardiology 1, 2
The European Society of Cardiology recommends that patients with signs of cardiogenic shock undergo rapid evaluation of volume status and receive norepinephrine to maintain a mean arterial pressure ≥65 mmHg, followed by echocardiographic assessment to determine the etiology and guide definitive treatment 1, 2

The European Society of Intensive Care Medicine recommends initiating norepinephrine as the first-line vasopressor after rapid assessment of volume status to maintain a mean arterial pressure ≥65 mmHg 3, 4
The British Journal of Anaesthesia suggests performing a passive leg raise test to assess fluid responsiveness, and if positive, administering crystalloids, preferably lactated Ringer's solution 5
The European Society of Cardiology recommends continuous monitoring of ECG, blood pressure, oxygen saturation, and urine output, as well as assessing arterial blood gases and serum lactate as markers of tissue perfusion 1, 2, 3, 4

The European Society of Cardiology recommends considering dobutamine (2.5-10 μg/kg/min) if there is evidence of low cardiac output in patients with cardiogenic shock due to ventricular dysfunction 1, 2
The European Society of Cardiology suggests considering thrombolytic therapy or mechanical intervention in patients with obstructive shock (massive pulmonary embolism) after diagnostic confirmation 2, 4

The European Society of Cardiology recommends administering supplemental oxygen to maintain saturation >94% 1, 2
The European Society of Intensive Care Medicine suggests considering endotracheal intubation if there is significant respiratory compromise 1, 2
The European Society of Intensive Care Medicine recommends monitoring response to treatment through clinical parameters (blood pressure, heart rate, peripheral perfusion, urine output) and laboratory parameters (lactate, SvO2) 3, 4

The American Heart Association recommends immediate intervention with fluid resuscitation, adjustment of vasopressor therapy, and consideration of alternative agents for patients with severe hypotension and tachycardia, as the current regimen may be inadequate and potentially harmful 6
Current therapy with norepinephrine and dobutamine may not achieve adequate hemodynamic stability, and adjustment of these medications may be necessary to optimize blood pressure and reduce tachycardia 6, 7
The European Society of Cardiology suggests that refractory shock may require additional or alternative agents, such as vasopressin or epinephrine, to achieve adequate blood pressure and perfusion 8
The American College of Cardiology recommends considering alternative inotropes, such as milrinone, which may cause less tachycardia than dobutamine, for patients with cardiogenic shock and preserved blood pressure 6, 8
Norepinephrine can cause tissue necrosis if extravasation occurs, and central line administration is preferred to minimize this risk 7